Invest like a master
For information and research only. Not investment advice.
13F filings

Hillhouse HHLR

Zhang Lei
Performance
Assuming an initial $100,000 · Benchmark: S&P 500
Hypothetical
Replication modeTop 5Top 10Main holdings
YTD1Y5Y8YAll
CompoundFixed

Gains are reinvested — principal and returns grow together.

$100k$200k$300k2019/022021/082024/032026/09$304k$125k
Backtest through 2026-09-10
After filingAt quarter endBenchmark · S&P 500
After filingbuys the holdings only once the filing is public — about 45 days after the quarter ends. The path someone could actually have taken.
At quarter endpretends the same holdings were bought on the last day of the quarter, before anyone could have known them. Not possible in reality — shown dashed for comparison only.
BenchmarkS&P 500 (SPY) total return over the same window — what doing nothing but holding the market would earn.

Hypothetical backtest — not a real trading record. Simulated on public data from 2019-02: each position is bought only after the filing became public (using no information unavailable at the time), with trading costs deducted, on a total-return basis. Past performance does not predict future results.

All metrics below are computed on the After-filing curve.
Return?
3.7%
Compound annual return over the sample.
Risk?
34.0%
How much returns swing (annualized stdev); lower is steadier.
Return vs risk?
0.28
Return ÷ volatility; higher is better.
Beat SPX?
−12.4%
Annualized gain over the S&P.
Excess?
−7.0%
The strategy's own annual excess, apart from the market.
Significance?
t=−0.69 · weak
t-value: how solid the excess is — higher is more reliable.
Max DD?
−71.4%
Largest peak-to-trough fall.
Leverage?
0.97×
How many times it rises and falls together with the market.
Longest recovery?
67 mo
Longest wait from a peak back to a new high.
About
Zhang Lei

Long-term growth investing spanning China and the U.S. Zhang Lei founded Hillhouse in 2005 with a piece of capital from Yale's endowment, took large early positions in companies like Tencent and held them for years, and became a leading figure in Chinese institutional investing—drawing some controversy in recent years. This is a growth-investing-style fund; investors interested in Chinese companies and growth stocks can track its filings over time.

Holdings & changes
Replication modeTop 5Top 10Main holdings
Current holdingsPosition changes
2026-Q2 filing · filed 2026-08-14
The replication holds all 35 names filed that quarter; the 30 largest are listed below, together 99.7% of the portfolio.
Main holdings · filed weights
TickerNameWeightvs last filing
LEGN
Legend Biotech Corporation American Depositary Shares
20.8%+14.3
FUTU
Futu Holdings Limited American Depositary Shares
20.0%+8.3
AVBP
ArriVent BioPharma, Inc. Common Stock
16.5%+11.0
MRVL
Marvell Technology Inc
5.9%+4.8
VIPS
Vipshop Hldgs LTD
5.6%+5.4
PDD
PDD Holdings Inc. American Depositary Shares
4.6%20.9
BEKE
KE Holdings Inc. American Depositary Shares (each representing three Class A Ordinary Shares)
3.9%
CTKB
Cytek Biosciences, Inc. Common Stock
3.6%+1.8
ALMR
ALMR
3.1%New
BABA
Alibaba Group Holding Limited American Depositary Shares, each represents eight Ordinary Shares
2.1%16.3
ODTX
ODTX
1.9%New
YSG
Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares
1.9%+1.0
NBP
Novabridge Biosciences
1.4%+0.5
CTNM
CTNM
1.3%+0.8
MAZE
MAZE
1.3%+0.7
API
Agora Inc
1.0%+0.6
TSM
Taiwan Semiconductor Manufacturing Company Ltd.
0.9%
SGMT
SGMT
0.7%
NTES
NetEase, inc.
0.5%
GE
GE Aerospace
0.5%
LITE
Lumentum Holdings Inc. Common Stock
0.3%
NVDA
Nvidia Corp
0.3%
TUYA
TUYA
0.3%
GLW
Corning Incorporated
0.3%
COHR
Coherent Corp.
0.3%
BULL
BULL
0.2%
INTC
Intel Corp
0.2%
PACB
Pacific Biosciences Calif IN
0.2%
TXN
Texas Instruments Incorporated
0.2%
MOGU
MOGU
0.2%
Risk
The replication is built from public filings: ~45-day lag, US long stock positions only; replication returns are not the fund’s real returns, and the manager may have traded since.
Past / backtested performance does not predict the future. Data and calculations may contain errors; we correct them when found. Masterfolio is an information service / publisher, not an investment adviser. Fund and manager names refer to their public filings only; no affiliation or endorsement.
Back
HomePro ToolsMy libraryAccount
Zhang Lei Portfolio & 13F Holdings 2026 — Replication Backtest · Masterfolio